The tweet was deleted by the author.
But we saved everything 🙂.
Castle Biosciences will present new research developed in partnership with Mayo Clinic at Digestive Disease Week in Chicago. The studies, featured in two poster sessions, focus on the role of the TissueCypher test in improving molecular risk stratification for patients with digestive disorders.
According to Castle Biosciences, the findings support the potential for more accurate risk assessment and targeted patient management. The presentation is scheduled during Digestive Disease Week from May 2 to 5.
View post on X Loading...
Castle Biosciences has previously highlighted the role of its laboratory teams in advancing diagnostic tests for patient care. During Lab Week, the company recognized professionals contributing to innovation in this area. Additional background is available in the article on laboratory professionals at Castle Biosciences.